← Back to Clinical Trials
Recruiting NCT04005508

NCT04005508 OSA and CV Outcomes in Patients With High Risk AF

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04005508
Status Recruiting
Phase
Sponsor National University of Singapore
Condition Atrial Fibrillation
Study Type OBSERVATIONAL
Enrollment 1,365 participants
Start Date 2019-07-01
Primary Completion 2025-06-30

Trial Parameters

Condition Atrial Fibrillation
Sponsor National University of Singapore
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,365
Sex ALL
Min Age 22 Years
Max Age 99 Years
Start Date 2019-07-01
Completion 2025-06-30
Interventions
Overnight sleep study

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The POACH study is part of the Cardiosleep research program. It is a prospective, observational, multicentre study conducted in Singapore. The recruitment target is 1365 patients. Eligible patients with AF and high cardiovascular risk will be recruited for a home-based sleep study using a FDA-approved portable device. The patients will be divided into 2 groups based on the presence or absence of OSA using apnoea-hypopnoea index ≥ 15 events/hour. The AF will be treated as per local standard practice. Participation in the POACH study will not affect the management of AF. Follow-up will be conducted every 6 months until the median follow-up duration has reached 2 years. The primary endpoint is a four-component composite of all-cause mortality, myocardial infarction, stroke and heart failure hospitalisation. Antecubital venous blood samples will be taken from the patients in the morning after the sleep study for targeted mass spectrometry which will measure 83 circulating metabolites. Sparse Principal Component Analysis will be used for data reduction. Identification of distinct associations between metabolic perturbations and OSA will be performed.

Eligibility Criteria

Inclusion Criteria: 1. Age 22 or above 2. Known AF, including paroxysmal, persistent or permanent AF 3. High cardiovascular risk, defined as one or more of the following: * hypertension * diabetes mellitus * stroke * significant coronary artery disease (at least one stenosis of \>50% diameter in at least one major epicardial artery based on CT or conventional coronary angiography, positive stress test \[treadmill, myocardial perfusion scan, or stress echocardiography\], previous percutaneous coronary intervention, or previous coronary artery bypass surgery) * chronic kidney disease (excluding polycystic kidney disease) with an estimated glomerular filtration rate of \<60 ml/min/1.73m2, * 10-year risk of cardiovascular disease of 15% or greater on the basis of the Framingham risk score, or * age of 75 years or older Exclusion Criteria: 1. Known OSA on regular CPAP treatment 2. Valvular AF (moderate/severe mitral stenosis or mechanical heart valve) 3. Permanent pacemaker implantation 4.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology